Cancer Cells Can Treat Tumors – Part 2 of 3
And “At that time, we knew that anti-CD47 antibody therapy selectively killed only cancer cells without being toxic to most normal cells, although we didn’t know why”. Now, the new research has shown that calreticulin exists in a variety of cancers, including some types of leukemia, non-Hodgkin’s lymphoma and bladder, sagacity and ovarian cancers.
So “This research demonstrates that the reason that blocking the CD47 ‘don’t eat me’ signal works to kill cancer is that leukemias, lymphomas and many rugged tumors also display a calreticulin ‘eat me’ signal,” Dr Irving Weissman, director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and a co-principal investigator of the study, said in the release. “The check out also shows that most normal cell populations don’t display calreticulin and are, therefore, not depleted when we expose them to a blocking anti-CD47 antibody”.
You must be logged in to post a comment.